• Transcenta agreed to sell its Hangzhou CDMO manufacturing assets to WuXi Biologics’ Hangzhou unit for RMB 190 million, subject to adjustments.
• Assets include a GMP facility property, related structures, equipment, and associated contracts; Transcenta retains drug pipeline and biomanufacturing technology IP.
• Payment split into four tranches: RMB 95 million, RMB 28.5 million, RMB 38 million, then RMB 28.5 million within six months of final completion.
• Transcenta expects the first three payments in 2026, final payment in Q1 2027, with proceeds earmarked for working capital and pipeline development.
• CDMO unit revenue was RMB 9.02 million in 2024 and RMB 6.38 million in 2025; Transcenta estimates an about RMB 280 million disposal loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12276399), on August 06, 2026, and is solely responsible for the information contained therein.